AstraZeneca sees Higher Revenue, Profit in 2024 on Resilient Demand
Feb 8 Reuters AstraZeneca on Thursday forecast higher revenue and profit for 2024, betting on strong uptake of its infant RSV shot and resilient demand for its cancer and rare blood disorder drugs. Almost a decade after AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot, who took the helm in 2012, has […]